Skip to main content
. Author manuscript; available in PMC: 2016 Apr 15.
Published in final edited form as: Cancer Res. 2015 Mar 13;75(8):1682–1690. doi: 10.1158/0008-5472.CAN-14-1855

Figure 1. VEGF-A silencing in WM1617, C8161 and A2058 melanoma cells by plasmid-based shRNA.

Figure 1

A, VEGF-A expression was examined in the cell supernatants of a panel of melanoma cells, including WM1617, WM983C, 1205Lu, A2058, and C8161 cells (left panel). VEGF-A expression was confirmed in 100 µg of protein lysates harvested from WM1617, WM983C, 1205Lu, A2058, and C8161 cells (right panel). WM1617, C8161 and A2058 cells displayed the highest VEGF-A expression. B, VEGF-A KD in 100 µg of protein lysates harvested from WM1617, C8161 and A2058 cells stably transfected with nontarget control or VEGF-A shRNA (sh1) was confirmed using a human VEGF-A ELISA kit. *, P<0.05. C, qRT-PCR confirmed VEGF-A downregulation in WM1617, C8161 and A2058 VEGF-A KD (sh1) cells compared to nontarget controls. *, P<0.05.